Cite
HARVARD Citation
Peyrin-Biroulet, L. et al. (n.d.). DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn's Disease: Results from the STARDUST trial. Journal of Crohn's and colitis. pp. i132-i134. [Online].